Esperion Therapeutics Inc Revenue Growth Rates (ESPR), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Esperion Therapeutics Inc   (NASDAQ: ESPR)
 

ESPR's Revenue Growth by Quarter and Year

Esperion Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ESPR Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 80.10
FY 80.10

ESPRs Annual Revenue
Esperion Therapeutics Inc 's Revenue in the fiscal year 2025 $ 403.14 millions
Esperion Therapeutics Inc 's Revenue in the fiscal year 2024 $ 332.31 millions
Esperion Therapeutics Inc 's Revenue in the fiscal year 2023 $ 116.33 millions
Esperion Therapeutics Inc 's Revenue in the fiscal year 2022 $ 75.48 millions
Esperion Therapeutics Inc 's Revenue in the fiscal year 2021 $ 78.45 millions




ESPR Revenue first quarter 2026 Y/Y Growth Comment
Esperion Therapeutics Inc reported Revenue improvement of 23.24% year on year in the first quarter 2026, to $ 80.10 millions, this is lower than Esperion Therapeutics Inc 's recent average Revenue surge of 252.77%.

Looking into first quarter 2026 results within Major Pharmaceutical Preparations industry 96 other companies have achieved higher Revenue growth. While Esperion Therapeutics Inc ' s Revenue rise of 23.24% ranks overall at the positon no. 2202 in the first quarter 2026.


ESPR Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 143.74 % 114.29 % 71.36 %
3rd Quarter September - 69.11 % 51.99 % 78.98 %
2nd Quarter June - 11.59 % 186.27 % 36.89 %
1st Quarter March 23.24 % -52.81 % 466.13 % 29.14 %
FY   - 21.32 % 185.64 % -

Financial Statements
Esperion Therapeutics Inc 's first quarter 2026 Revenue $ 80.10 millions ESPR's Income Statement
Esperion Therapeutics Inc 's first quarter 2025 Revenue $ 65.00 millions Quarterly ESPR's Income Statement


ESPR Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 92.93 % 33.86 % -5.06 %
3rd Quarter September - 5.97 % -30.07 % 31.72 %
2nd Quarter June - 26.75 % -46.4 % 6 %
1st Quarter March -52.45 % -5.95 % 327.1 % 29.28 %
FY (Year on Year)   - 21.32 % 185.64 % -


Back to ESPR Growth rate Comparisons >> Back to ESPR Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #97
Healthcare Sector #277
Overall #2202

Revenue Y/Y Growth Statistics
High Average Low
4783.7 % 252.77 % -71.25 %
(Mar 31 2021)   (Jun 30 2021)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #97
Healthcare Sector #277
Overall #2202
Revenue Y/Y Growth Statistics
High Average Low
4783.7 % 252.77 % -71.25 %
(Mar 31 2021)   (Jun 30 2021)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Esperion Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
11434.57 % 437.38 % -99.32 %
(Jun 30 2020)  


ESPR's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Esperion Therapeutics Inc disclosed fall in Revenue from the fourth quarter by -52.45% to $ 80.10 millions, from $ 168.45 millions achived in the previous reporting period.

But that's not important problem, as Esperion Therapeutics Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 107 other companies have achieved higher Revenue quarter on quarter growth. While Esperion Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 2375.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #108
Healthcare Sector #305
Overall #2375
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #108
Healthcare Sector #305
Overall #2375
Revenue Q/Q Growth Statistics
High Average Low
11434.57 % 437.38 % -99.32 %
(Jun 30 2020)  


ESPR's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Esperion Therapeutics Inc disclosed fall in Revenue from the fourth quarter by -52.45% to $ 80.10 millions, from $ 168.45 millions achived in the previous reporting period.

But that's not important problem, as Esperion Therapeutics Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 107 other companies have achieved higher Revenue quarter on quarter growth. While Esperion Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 2375.


Esperion Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)
Cumulative Revenue 12 Months Ending $ 418.24 $ 403.14 $ 303.80 $ 268.13 $ 259.57
Y / Y Revenue Growth (TTM) 61.13 % 21.31 % 2.83 % -3.48 % 12.99 %
Year on Year Revenue Growth Overall Ranking # 726 # 32 # 33 # 42 # 38
Seqeuential Revenue Change (TTM) 3.75 % 32.7 % 13.31 % 3.29 % -21.89 %
Seq. Revenue Growth (TTM) Overall Ranking # 2824 # 730 # 1043 # 469 # 118


Cumulative Revenue growth Comment
Although Esperion Therapeutics Inc 's Annual Revenue growth year on year were below company's average 252.77% , Revenue announced in the Mar 31 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 61.13% year on year, from 21.31% in Dec 31 2025.

In the Healthcare sector 123 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 32 to 726.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 140
Healthcare Sector # 124
Overall # 726

Revenue TTM Y/Y Growth Statistics
High Average Low
4783.7 %
 252.77 %
-71.25 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 140
Sector # 407
S&P 500 # 2824
Cumulative Revenue growth Comment
Although Esperion Therapeutics Inc 's Annual Revenue growth year on year were below company's average 252.77% , Revenue announced in the Mar 31 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 61.13% year on year, from 21.31% in Dec 31 2025.

In the Healthcare sector 123 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 32 to 726.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 140
Healthcare Sector # 124
Overall # 726

Revenue TTM Y/Y Growth Statistics
High Average Low
4783.7 %
252.77 %
-71.25 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 140
Sector # 407
S&P 500 # 2824




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ESPR's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Mar 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2026
Maravai Lifesciences Holdings Inc 40.24%$ 40.237 millions
Heartflow Inc 40.21%$ 40.207 millions
Agenus Inc40.18%$ 40.181 millions
Electrocore Inc 39.64%$ 39.636 millions
Caredx Inc 38.99%$ 38.986 millions
Natera Inc 38.82%$ 38.821 millions
Supernus Pharmaceuticals inc 38.63%$ 38.633 millions
Xeris Biopharma Holdings Inc 38.27%$ 38.271 millions
Apyx Medical Corp37.62%$ 37.623 millions
Novo Nordisk A37.57%$ 37.575 millions
Aim Immunotech Inc 37.50%$ 37.500 millions
Aclaris Therapeutics Inc 37.18%$ 37.182 millions
Kyntra Bio Inc 36.47%$ 36.473 millions
Precipio inc 36.15%$ 36.153 millions
Xenetic Biosciences Inc 36.01%$ 36.015 millions
The Pennant Group Inc 35.99%$ 35.990 millions
Beone Medicines Ltd 35.44%$ 35.438 millions
Adaptive Biotechnologies Corporation35.14%$ 35.145 millions
Brightspring Health Services Inc 35.10%$ 35.104 millions
Vivos Inc34.84%$ 34.844 millions
Neuroone Medical Technologies Corp34.29%$ 34.290 millions
Insulet Corporation33.87%$ 33.866 millions
Sonida Senior Living Inc 33.41%$ 33.407 millions
Zomedica Corp 32.42%$ 32.418 millions
Krystal Biotech Inc 31.95%$ 31.949 millions
Northwest Biotherapeutics Inc31.73%$ 31.733 millions
Geron Corporation30.89%$ 30.892 millions
Ceribell Inc 30.56%$ 30.564 millions
Scientific Industries Inc 30.22%$ 30.224 millions
Vericel Corporation30.09%$ 30.090 millions


About Esperion Therapeutics Inc Revenue Growth Rates (ESPR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Esperion Therapeutics Inc (CIK 1434868).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-032870
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Esperion Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.